EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

EyePoint (Nasdaq: EYPT) granted inducement non‑statutory stock options to nine new employees on December 15, 2025 under Nasdaq Listing Rule 5635(c)(4).

The company awarded options to purchase an aggregate of 137,000 shares at an exercise price of $16.40 per share (closing price on December 15, 2025). Options have a 10‑year term and vest over 4 years: 25% on the first anniversary and the remainder in equal monthly installments over the following three years, subject to continued service. Grants were approved by the Compensation Committee.

Key Figures

Inducement option shares 137,000 shares Non-statutory stock options granted to new employees

New employees 9 employees Recipients of inducement stock option awards

Exercise price $16.40 per share Closing price on December 15, 2025 (option grant date)

Option term 10 years Duration of inducement stock options

Vesting period 4 years Inducement options vesting schedule length

Initial vesting tranche 25% Portion vesting on first anniversary of grant date

Current share price $16.40 Pre-news close vs. option exercise price

Shares vs 52-week range $3.91–$19.11 52-week low and high before this filing

Market Reality Check

$16.40 Last Close

Volume Volume 777,955 is at 0.69x the 20-day average, indicating subdued trading activity before this filing. low

Technical Shares at $16.40 are trading above the 200-day MA of $10.05, reflecting a pre-existing uptrend.

Peers on Argus 2 Up

Among close biotech peers, QURE and URGN show notable gains of 4.29% and 4.34%, while OCS and UPB are modestly negative. Mixed peer moves suggest this HR-related stock option news is company-specific rather than part of a coordinated sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 19	Clinical trial update	Positive	+2.3%	DSMC found no safety signals and backed continuation of Phase 3 DURAVYU trials.
Nov 17	Inducement grants	Neutral	+13.4%	Non-statutory stock options granted as inducement awards to seven new employees.
Nov 05	Earnings release	Negative	-11.1%	Q3 2025 showed sharply lower revenue and a wider net loss as trials advanced.
Nov 03	Conference participation	Neutral	-4.9%	Announced attendance at multiple November healthcare investor conferences and webcasts.
Oct 29	Earnings date notice	Neutral	-4.2%	Scheduled Q3 2025 earnings release and investor call details for early November.

Pattern Detected

Recent history shows positive clinical milestones and capital-raising updates leading to aligned price moves, while a wider quarterly loss also aligned with a negative reaction. Conference and scheduling updates saw moderate declines, indicating limited standalone impact.

Recent Company History

Over the last few months, EYPT reported several key developments. On Nov 19, 2025, a positive DSMC recommendation for pivotal Phase 3 DURAVYU™ wet AMD trials with over 900 patients aligned with a +2.29% move. Earlier, inducement option grants on Nov 14, 2025 preceded a +13.43% reaction. The Nov 5, 2025 Q3 results, featuring a wider loss, saw shares fall 11.1%. Conference participation and earnings-date announcements in late October and early November drew smaller single-digit declines.

Market Pulse Summary

This announcement details inducement grants of 137,000 non-statutory stock options to nine new employees, issued at an exercise price of $16.40 with a 10-year term and four-year vesting. It follows recent clinical, earnings, and financing updates that shaped EyePoint’s trajectory. Investors may track how ongoing equity compensation and prior capital raises interact with trial progress, particularly pivotal DURAVYU™ studies, when assessing longer-term dilution and execution risk.

Key Terms

non-statutory stock options financial

"granted non-statutory stock options to new employees as inducement awards"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

nasdaq listing rule 5635(c)(4) regulatory

"outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

WATERTOWN, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 137,000 shares of EyePoint common stock to nine new employees. The stock options were granted on December 15, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $16.40 per share, the closing price of EyePoint’s common stock on December 15, 2025. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with EyePoint through the applicable vesting dates.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration with expected topline data beginning in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema is expected in the first quarter of 2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901.

DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

For EyePoint:

Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
Tanner.Kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

What did EyePoint (EYPT) grant on December 15, 2025?

EyePoint granted non‑statutory stock options to nine new employees to purchase an aggregate of 137,000 shares.

What is the exercise price and term of the EYPT inducement options?

The options have an exercise price of $16.40 per share and a 10‑year term.

How do the EYPT options vest and when do shares become exercisable?

Options vest over 4 years: 25% at the first anniversary, then monthly vesting over the next three years, subject to continued service.

Why did EyePoint use Nasdaq Listing Rule 5635(c)(4) for these grants?

The grants were made as inducement awards outside the company’s LTIP in accordance with Nasdaq Listing Rule 5635(c)(4) for new hires.

Will the 137,000 option grants immediately dilute EYPT shareholders?

The grants are options, not issued shares; dilution would occur only if and when options are exercised.

Who approved the EYPT option grants and when were they granted?

The Compensation Committee approved the grants, which were granted on December 15, 2025.